In addition to cirmtuzumab, a second generation mAb targeting ROR1 has been created: 5F1-B10, which induced apoptosis in melanoma and bladder cancer cells by inhibiting pro-survival ROR1 signaling [29,176]. This evidence concerns the gene ROR1 and urinary bladder cancer.